📖
Esketamine use in real-world clinical practice in patients with treatment-resistant depression
Ismael Conejero, Raquel Alvarez García, Alejandro Porras-Segovia, Ana María de Granda Beltrán, Sergio Benavente López, Ezequiel Di Stasio, Lucía Albarracín-García, Jorge Lopez-Castroman, Philippe Courtet, Enrique Baca-Garcia

Esketamine use in real-world clinical practice in patients with treatment-resistant depression

Science & Mathematics Published 2025 Verification Pending

Overview & Synopsis

Background: Esketamine has been shown to produce a major antidepressant response in patients with treatment-resistant depression (TRD). We aimed to evaluate the factors associated with achieving remission in these individuals. Methods: The study was carried out across four psychiatry departments in Madrid, Spain. Patients aged over 18 years were included if they received esketamine as an augmentation treatment for TRD. Standard esketamine protocol included an induction phase (2 administrations per week for 4 weeks) and a maintenance phase (1 administration per week for 5 to 8 weeks). A subsequent treatment continuation phase was also proposed. Clinical data and scores at the Clinical Global Impression scales were measured following each esketamine administration. Results: Sixty-five patients initiated the treatment, and 45 patients (69.2%) completed the standard protocol. The median number of esketamine administrations was 19. The mean age of the sample was 53.09 and 52.3% of the patients were females. Out of the whole sample, 36 (55%) of the patients achieved remission over the follow-up. Remission rates elevated to 67% in those who completed the standard protocol, and to 70% in those having received more than 19 esketamine administrations. Achieving remission over the follow-up was associated with the absence of dissociative symptoms, and with completing the standard esketamine protocol (OR=0.229, p=0.045; and OR=4.538, p=0.025, respectively). Receiving more than 19 esketamine administrations was associated with remission over the follow-up (OR=6.513, p=0.006). Conclusions: Our results suggest that extending the numbers of esketamine administration may increase the chances to obtain remission. Adverse effects did not impact the treatment course.

Indexed from repository: HAL Open Science (hal.science)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title Esketamine use in real-world clinical practice in patients with treatment-resistant depression
Author / Organization Ismael Conejero, Raquel Alvarez García, Alejandro Porras-Segovia, Ana María de Granda Beltrán, Sergio Benavente López, Ezequiel Di Stasio, Lucía Albarracín-García, Jorge Lopez-Castroman, Philippe Courtet, Enrique Baca-Garcia
Subject & Discipline Multidisciplinary Academic Open Research
Categories Science & Mathematics
Publication Year 2025
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website HAL Open Science (hal.science)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-187885
Original Source Link Visit Source Page on hal.science »